Mediterranean Diet and Protein-Sparing Modified Diet for Metabolic Syndrome in Liver Transplant Recipients
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02174783 |
Recruitment Status :
Terminated
First Posted : June 26, 2014
Last Update Posted : March 14, 2017
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Liver Transplantation Metabolic Syndrome X Obesity | Other: Control group Other: Mediterranean diet Other: Protein-Sparing Modified Fast (PSMF) | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 25 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | The Safety and Efficacy of Mediterranean Diet and Protein-Sparing Modified Diet on Obesity and Metabolic Syndrome in Liver Transplant Recipients: A Randomized Clinical Trial |
Study Start Date : | June 2014 |
Actual Primary Completion Date : | January 2015 |
Actual Study Completion Date : | April 2015 |

Arm | Intervention/treatment |
---|---|
Active Comparator: Control group
Standard of care group
|
Other: Control group
Patient will be provided with basic nutrition educational materials that outline principles of a healthy diet, including: moderation, portion control, increased intakes of fruits, vegetables and whole grains and reduced intakes of saturated fat, salt and sugar. Brief education will be provided by the hepatologist without dietitian referral. |
Experimental: Mediterranean diet
Mediterranean diet for 6 months
|
Other: Mediterranean diet
Patient will receive verbal diet instruction from the dietitian or from the hepatologist who has received instruction from the dietitian on following the Mediterranean diet. |
Experimental: Protein-Sparing Modified Fast (PSMF)
PSMF for 6 months
|
Other: Protein-Sparing Modified Fast (PSMF)
Patient will be referred to the dietitian for an appointment to discuss the PSMF plan. Protein needs of 1.5 grams/kilogram will be calculated based on patient's actual body weight. Patient will receive verbal instruction from the dietitian, as well as printed materials for reference at home. Dietitian will provide a list of allowed and prohibited foods as per Cleveland Clinic's PSMF diet standards. |
- Weight loss [ Time Frame: 6 months ]
- Number of Participants with Serious and Non-Serious Adverse Events [ Time Frame: 6 months ]Investigate the safety of the mediterranean diet and PSMF in post liver transplant patients
- Change in Hb A1c compared to baseline [ Time Frame: 6 months ]
- Change in HDL and LDL compared to baseline [ Time Frame: 6 months ]
- Change in triglyceride compared to baseline [ Time Frame: 6 months ]
- Change in blood pressure compared to baseline [ Time Frame: 6 months ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Adult patients > 18 years old who had a successful liver transplant at least 1 year prior to enrollment who also have a BMI>30 with previous failed attempts at weight loss via conventional methods. In addition to one of the following:
- Triglyceride (TG)>150 mg/dl or specific treatment for this lipid abnormality
- HDL <40 mg/dl in females and <50 mg/dl in males or specific treatment of this lipid abnormality
- Systolic BP >130 or diastolic BP >85 mm Hg or treatment for previously diagnosed hypertension
- Fasting plasma glucose >100 mg/dl or previously diagnosed type 12 diabetes
Exclusion Criteria:
- Significant behavioral issues that would interfere with compliance
- Lack of readiness to change (pre-contemplation, contemplation or preparation stages)
- Previous bariatric surgery
- Pregnant or planning to become pregnant
- History of a documented eating disorder (e.g. bulimia)
- History of kidney stones

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02174783
United States, Ohio | |
Cleveland Clinic | |
Cleveland, Ohio, United States, 44195 |
Principal Investigator: | mohammed Eyad Yaseen Alsabbagh, MD | The Cleveland Clinic | |
Study Director: | Naim Alkhouri, MD | The Cleveland Clinic |
Responsible Party: | The Cleveland Clinic |
ClinicalTrials.gov Identifier: | NCT02174783 |
Other Study ID Numbers: |
PTMS-9500 |
First Posted: | June 26, 2014 Key Record Dates |
Last Update Posted: | March 14, 2017 |
Last Verified: | July 2014 |
Weight Loss Diet, Mediterranean Diet, Reducing protein sparing modified diet |
Obesity Metabolic Syndrome Syndrome Disease Pathologic Processes Overnutrition Nutrition Disorders |
Overweight Body Weight Insulin Resistance Hyperinsulinism Glucose Metabolism Disorders Metabolic Diseases |